Luspatercept

Resumen

Alternativas con registro en Colombia

• Eritropoyetina
• Darbepoetina Alfa · costo anual estimado $ 2.933.870
• Metoxipolietilenglicol-epoetina Beta · costo anual estimado $ 2.456.815

Estudios clínicos principales

• BELIEVE: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
  Fase 3 · 2016 · 336 participantes · Celgene · NCT02604433 · PubMed 30504333 · PubMed 30617198
• MEDALIST: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
  Fase 3 · 2016 · 229 participantes · Celgene · NCT02631070 · PubMed 31914241 · PubMed 32089218
• COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediat
  Fase 3 · 2019 · 363 participantes · Celgene · NCT03682536
• INDEPENDENCE: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2
  Fase 3 · 2021 · 313 participantes · Celgene · NCT04717414

Enfermedades relacionadas

• Trombosis y anticoagulación
• Anemia
• Cáncer (todos)
• Síndromes mielodisplásicos y mieloproliferativos

Fuentes

• Etiqueta FDA (DailyMed): Reblozyl
• EMA: Reblozyl